Table 2.
List of studies demonstrating protective and/or deleterious effect of KIR genes/receptors to BK viremia and/or risk for BKVAN.
| References | Factor | n | Clinical Effect |
|---|---|---|---|
| Trydzenskaya et al., 2013 [125] | Low number of aKIR KIR3DS1 neg Tel B KIR haplotype |
48 | In R—↑ BKVAN In R—↑ BKVAN In R—↓ BK viremia and BKVAN |
| Brochot et al., 2016 [127] | KIR haplotype aKIR number R:KIR2DS1/C1C2 + D:C2 R:KIR2DS2/C1C2 + D:C1 |
103 | No association with BK viremia No association with BK viremia ↑ BKV reactivation ↑ BKV reactivation |
| Trotter et al., 2018 [126] | KIR2DS4 | 1010 | No association with BK viremia |
| Kovacevic Vojtusek et al., 2019 [67] | Lacking aKIR KIR haplotype AA R:KIR AA pos + D:Cw7 neg |
23 | In R—↑ BKVAN ↑ BKVAN ↑ BKVAN |
aKIR—activating KIR receptors; BKV—BK virus; BKVAN—BK virus-associated nephropathy; C1—HLA-C KIR ligands group 1; C2—HLA-C KIR ligands group 2; D—donor; n—number of recipients/donors included in the study; neg—negative; R—recipient; ↑—increased risk for; ↓—decreased risk for.